Logo image of MLTX

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Stock Fundamental Analysis

USA - NASDAQ:MLTX - KY61559X1045 - Common Stock

10.1 USD
+0.29 (+2.96%)
Last: 10/31/2025, 8:00:55 PM
10.05 USD
-0.05 (-0.5%)
After Hours: 10/31/2025, 8:00:55 PM
Fundamental Rating

2

MLTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. MLTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MLTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MLTX has reported negative net income.
In the past year MLTX has reported a negative cash flow from operations.
MLTX had negative earnings in each of the past 5 years.
MLTX had a negative operating cash flow in each of the past 5 years.
MLTX Yearly Net Income VS EBIT VS OCF VS FCFMLTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of MLTX (-38.29%) is better than 61.05% of its industry peers.
Looking at the Return On Equity, with a value of -49.80%, MLTX is in the better half of the industry, outperforming 66.48% of the companies in the same industry.
Industry RankSector Rank
ROA -38.29%
ROE -49.8%
ROIC N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLTX Yearly ROA, ROE, ROICMLTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MLTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLTX Yearly Profit, Operating, Gross MarginsMLTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MLTX has more shares outstanding
MLTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MLTX Yearly Shares OutstandingMLTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M
MLTX Yearly Total Debt VS Total AssetsMLTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.33 indicates that MLTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.33, MLTX is in the better half of the industry, outperforming 66.29% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that MLTX is not too dependend on debt financing.
MLTX has a Debt to Equity ratio of 0.21. This is in the lower half of the industry: MLTX underperforms 68.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 2.33
ROIC/WACCN/A
WACCN/A
MLTX Yearly LT Debt VS Equity VS FCFMLTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 16.65 indicates that MLTX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 16.65, MLTX belongs to the best of the industry, outperforming 92.32% of the companies in the same industry.
A Quick Ratio of 16.65 indicates that MLTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 16.65, MLTX belongs to the best of the industry, outperforming 92.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.65
Quick Ratio 16.65
MLTX Yearly Current Assets VS Current LiabilitesMLTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MLTX have decreased strongly by -205.49% in the last year.
EPS 1Y (TTM)-205.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.80% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-77.76%
EPS Next 2Y-40.16%
EPS Next 3Y-22.35%
EPS Next 5Y12.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLTX Yearly Revenue VS EstimatesMLTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B
MLTX Yearly EPS VS EstimatesMLTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLTX Price Earnings VS Forward Price EarningsMLTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLTX Per share dataMLTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as MLTX's earnings are expected to decrease with -22.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-40.16%
EPS Next 3Y-22.35%

More info and screens

0

5. Dividend

5.1 Amount

MLTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ:MLTX (10/31/2025, 8:00:55 PM)

After market: 10.05 -0.05 (-0.5%)

10.1

+0.29 (+2.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-18 2025-11-18/bmo
Inst Owners95.1%
Inst Owner Change-1.05%
Ins Owners11.02%
Ins Owner Change0.13%
Market Cap648.72M
Revenue(TTM)N/A
Net Income(TTM)-176158800
Analysts87.5
Price Target22.03 (118.12%)
Short Float %8.66%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.18%
Min EPS beat(2)-18.26%
Max EPS beat(2)17.89%
EPS beat(4)1
Avg EPS beat(4)-11.14%
Min EPS beat(4)-26.1%
Max EPS beat(4)17.89%
EPS beat(8)3
Avg EPS beat(8)-2.84%
EPS beat(12)7
Avg EPS beat(12)3.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-72.64%
PT rev (3m)-71.97%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-18.47%
EPS NY rev (1m)-0.13%
EPS NY rev (3m)-14.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.83
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-2.78
EYN/A
EPS(NY)-3.71
Fwd EYN/A
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS0
BVpS5.51
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.29%
ROE -49.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.25%
ROA(5y)-130.19%
ROE(3y)-45.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.65
Quick Ratio 16.65
Altman-Z 2.33
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)797.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-205.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
EPS Next Y-77.76%
EPS Next 2Y-40.16%
EPS Next 3Y-22.35%
EPS Next 5Y12.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-156.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-70.43%
EBIT Next 3Y-18.11%
EBIT Next 5YN/A
FCF growth 1Y-295.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-295.11%
OCF growth 3YN/A
OCF growth 5YN/A

MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ

Can you provide the ChartMill fundamental rating for MOONLAKE IMMUNOTHERAPEUTICS?

ChartMill assigns a fundamental rating of 2 / 10 to MLTX.


What is the valuation status of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MOONLAKE IMMUNOTHERAPEUTICS (MLTX). This can be considered as Overvalued.


Can you provide the profitability details for MOONLAKE IMMUNOTHERAPEUTICS?

MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a profitability rating of 1 / 10.


Can you provide the financial health for MLTX stock?

The financial health rating of MOONLAKE IMMUNOTHERAPEUTICS (MLTX) is 5 / 10.